HC Wainwright Issues Pessimistic Forecast for AGMB Earnings

AgomAb Therapeutics NV (NASDAQ:AGMB) – Equities researchers at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for AgomAb Therapeutics in a research report issued on Thursday, August 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.96) per share for the year, down from their previous forecast of ($1.78). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for AgomAb Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for AgomAb Therapeutics’ FY2027 earnings at ($2.08) EPS, FY2028 earnings at ($1.80) EPS, FY2029 earnings at ($1.86) EPS and FY2030 earnings at ($1.83) EPS.

A number of other equities research analysts also recently weighed in on AGMB. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.00.

AgomAb Therapeutics Stock Up 3.5%

Shares of NASDAQ AGMB opened at $13.68 on Monday. AgomAb Therapeutics has a 12 month low of $8.75 and a 12 month high of $17.82. The stock’s 50-day simple moving average is $12.59.

AgomAb Therapeutics (NASDAQ:AGMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.